Creo Medical Group PLC (CREO.L)
LSE · GBp · Healthcare · Medical Devices
£11.25 (+0.00%) as of
Key statistics
- Market cap
- 50.53M
- Forward P/E
- -8.65
- EPS (TTM)
- -0.10
- Dividend yield
- 0.00%
- 52-week range
- 9.50 – 18.50
- Beta
- 0.96
- Revenue (TTM)
- 7M
- Profit margin
- -287.14%
- Analyst target
- £55.00
- Volume
- 93.38k
About Creo Medical Group PLC
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. It also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, the company provides injection needles, hemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, it offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Chepstow, United Kingdom
- Employees
- 104
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.